Inhibition of AKt/mTOR signaling by the dietary flavonoid fisetin

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 995-1001

  Syed, Deeba N ^a   Adhami, Vaqar M ^a   Khan, Mohammad Imran ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Akt; Colon cancer; Fisetin; Lung cancer; Melanoma; Mtor; Myeloma; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FISETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OXYGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLON CANCER; CYTOTOXICITY; DISEASE COURSE; DOWN REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; LUNG CANCER; MELANOMA; MYELOMA; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FLAVONOIDS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84882737534     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990129     Document Type: Article

References (44)

1. Syed, D.N.; Afaq, F.; Mukhtar, H. Pomegranate derived products for cancer chemoprevention. Semin. Cancer Biol., 2007, 77(5), 377-385.
2. Marino, P.; Bertucci, F.; Goncalves, A.; Seror, V. Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients. Med. Sci., (Paris). 2012, 28(Spec No 1), 19-23.
3. Kundu, J.K.; Surh, Y.J. Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat. Res., 2005, 591(1-2), 123-146.
4. Moon, Y.J.; Wang, X.; Morris, M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro., 2006, 20(2), 187-210.
5. Hodek, P.; Trefil, P.; Stiborova, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450, Chem. Biol. Interact., 2002,139(1), 1-21.
6. Beecher, G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr., 2003,133(10), 3248S-3254S.
7. Kimira, M.; Arai, Y.; Shimoi, K.; Watanabe, S. Japanese intake of flavonoids and isoflavonoids from foods. J. Epidemiol., 1998, 8(3), 168-175.
8. Ishige, K.; Schubert, D.; Sagara, Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med., 2001, 30(4), 433-446.
9. Sagara, Y.; Vanhnasy, J.; Maher, P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation. J. Neurochem., 2004, 90(5), 1144-1155.
10. Maher, P.; Akaishi, T.; Abe, K. Flavonoid fisetin promotes ERK- dependent long-term potentiation and enhances memory. Proc.Natl. Acad. Sci. USA, 2006,103(44), 16568-16573.
11. Zheng, L.T.; Ock, J.; Kwon, B.M.; Suk, K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int. Immunopharmacol., 2008, 8(3), 484-494.
12. Syed, D.N.; Suh, Y.; Afaq, F.; Mukhtar, H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett., 2008, 265(2), 167-176.
13. Touil, Y.S.; Fellous, A.; Scherman, D.; Chabot, G.G. Flavonoid- induced morphological modifications of endothelial cells through microtubule stabilizatio. Nutr. Cancer, 2009, 61(3), 310-321.
14. Salmela, A.L.; Pouwels, J.; Varis, A.; Kukkonen, A.M.; Toivonen, P.; Halonen, P.K.; Perala, M.; Kallioniemi, O.; Gorbsky, G.J.; Kallio, M.J. Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis,2009, 30(6), 1032-1040.
15. Stone, A.; Sutherland, R.L.; Musgrove, E.A. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit. Rev. Oncog., 2012,17(2), 175-198.
16. Sung, B.; Pandey, M.K.; Aggarwal, B.B. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB- regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor- interacting protein-regulated IkappaBalpha kinase activation. Mol. Pharmacol., 2007, 71(6), 1703-1714.
17. Maher, P.; Salgado, K.F.; Zivin, J.A.; Lapchak, P.A. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res., 2007,1173, 117-125.
18. Lee, S.E.; Jeong, S.I.; Yang, H.; Park, C.S.; Jin, Y.H.; Park, Y.S. Fisetin induces Nrf2-mediated HO-1 expression through PKC-delta and p38 in human umbilical vein endothelial cells. J. Cell Biochem., 2011.
19. Hou, D.X.; Fukuda, M.; Johnson, J.A.; Miyamori, K.; Ushikai, M.; Fujii, M. Fisetin induces transcription of NADPH:quinone oxidoreductase gene through an antioxidant responsive element- involved activation. Int. J. Oncol., 2001,18(6), 1175-1179.
20. Jankun, J.; Selman, S.H.; Aniola, J.; Skrzypczak-Jankun, E. Nutraceutical inhibitors of urokinase: Potential applications in prostate cancer prevention and treatment. Oncol. Rep., 2006,16(2), 341-346.
21. Zhou, Q.; Lui, V.W.; Yeo, W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol., 2011, 7(10), 1149-1167.
22. Aksamitiene, E.; Kiyatkin, A.; Kholodenko, B.N. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance. Biochem. Soc. Trans., 2012, 40(1), 139-146.
23. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712), 1098-1101.
24. Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell, 2012,149(2), 274-293.
25. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.; Valero, V.; Guzman, M.; Botero, M.L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J.L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68(19), 8022-8030.
26. Song, M.S.; Salmena, L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol., 2012, 13(5), 283-296.
27. Tong, B.C.; Harpole, D.H. Jr. Molecular markers for incidence, prognosis, and response to therapy. Surg. Oncol. Clin. N. Am., 2012, 21(1), 161-175.
28. Papadimitrakopoulou, V.; Adjei, A.A. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy, J. Thorac. Oncol., 2006,1(7), 749-751.
29. Khan, N.; Afaq, F.; Khusro, F.H.; Mustafa Adhami, V.; Suh, Y.; Mukhtar, H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int. J. Cancer, 2012,130(7), 1695-1705.
30. Xu, J.; Ji, J.; Yan, X.H. Cross-talk between AMPK and mTOR in regulating energy balance. Crit. Rev. Food Sci. Nutr. 2012, 52(5), 373-381.
31. Brawley, O.W. Prostate cancer epidemiology in the United States, World J. Urol., 2012, 30(2), 195-200.
32. Higdon, J.V.; Delage, B.; Williams, D.E.; Dashwood, R.H. Cruciferous vegetables and human cancer risk: Epidemiologic evidence and mechanistic basis. Pharmacol. Res., 2007, 55(3), 224-236.
33. Khan, N.; Afaq, F.; Syed, D.N.; Mukhtar, H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis, 2008, 29(5), 1049-1056.
34. Khan, N.; Asim, M.; Afaq, F.; Abu Zaid, M.; Mukhtar, H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res., 2008, 55(20), 8555-8563.
35. Zhang, X.; Tang, N.; Hadden, T.J.; Rishi, A.K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta., 2011, 1813(11), 1978-1986.
36. Chien, C.S.; Shen, K.H.; Huang, J.S.; Ko, S.C.; Shih, Y.W. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol. Cell Biochem, 2010, 333(1-2), 169-180.
37. Jung, C.H.; Ro, S.H.; Cao, J.; Otto, N.M.; Kim, D.H. mTOR regulation of autophagy. FEBSLett., 2010, 584(7), 1287-1295.
38. Yang, Z.J.; Chee, C.E.; Huang, S.; Sinicrope, F. Autophagy modulation for cancer therap. Cancer Biol. Ther., 2011,11(2), 169-176.
39. Suh, Y.; Afaq, F.; Khan, N.; Johnson, J.J.; Khusro, F.H.; Mukhtar, H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis,2009, 57(8), 1424-1433.
40. Pandey, M.K.; Sung, B.; Ahn, K.S.; Aggarwal, B.B. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3- regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol., 2009, 75(3), 525-533.
41. Jang, K.Y.; Jeong, S.J.; Kim, S.H.; Jung, J.H.; Kim, J.H.; Koh, W.; Chen, C.Y.; Kim, S.H. Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. Cancer Lett., 2012, 319(2), 197-202.
42. Chen, M.B.; Shen, W.X.; Yang, Y.; Wu, X.Y.; Gu, J.H.; Lu, P.H. Activation of AMP-activated protein kinase is involved in vincristine- induced cell apoptosis in B16 melanoma cell. J. Cell Physiol., 2010.
43. Syed, D.N.; Afaq, F.; Maddodi, N.; Johnson, J.J.; Sarfaraz, S.; Ahmad, A.; Set-aletal/et-aluri, V.; Mukhtar, H. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/beta-catenin signaling and decreased mitf levels. J. Invest. Dermatol., 2011,131(6), 1291-1299.
44. Syed, D.N.; Adhami, V.M.; Chamcheu, J.C.; Rahul, K.L.; Mukhtar, H. Tumor regression in a 3-D melanoma model by the dietary flavonoid fisetin is associated with inhibition of Akt/mTOR signaling. Annual Meeting of the American Association for Cancer Research, Chicago, USA, March 31-April 4, 2012.